Les Laboratoires Servier SAS
http://www.servier.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Les Laboratoires Servier SAS
HUTCHMED Switches Clinical Strategy To Rely On Partnerships For Late-Stage Assets In US
Having initiated China-only Phase III trials with three oncology and autoimmune drug candidates, HUTCHMED is looking for partnerships to take the molecules to the clinic in the US.
AbbVie Cranks Up Temperature In IBD Market With Celsius Buyout
The drug maker is spending $250m to acquire privately held Celsius and its lead candidate, a monoclonal antibody targeting TREM1 in inflammatory bowel disease.
In Investing, Oncology Is Still King, But Other Indications Joining The Royal Court
Investing in oncology has diminished as more focus goes to clinical-stage firms, while investment in preclinical companies in areas like neurology has been heating up.
Asia Deal Watch: Argo Partners RNAi Programs With Novartis In Major Biobucks Pact
Plus deals involving Biocytogen/Radiance, Maruho/AOBiome, LGChem/Rhythm, IASO/Umoja, JW Therapeutics/2seventy and 13 other transactions.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice